Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Harvard Business School
McKesson
Boehringer Ingelheim
Baxter

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

ENCORAFENIB - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for encorafenib and what is the scope of patent protection?

Encorafenib is the generic ingredient in one branded drug marketed by Array Biopharma Inc and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Encorafenib has one hundred and twenty-six patent family members in forty-eight countries.

One supplier is listed for this compound.

Summary for ENCORAFENIB
International Patents:126
US Patents:11
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 35
Clinical Trials: 21
Patent Applications: 71
DailyMed Link:ENCORAFENIB at DailyMed
Recent Clinical Trials for ENCORAFENIB

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bristol-Myers Squibb (BMS)Phase 1/Phase 2
EADO - European Association of Dermato OncologyPhase 2
University of California, San FranciscoPhase 1/Phase 2

See all ENCORAFENIB clinical trials

Synonyms for ENCORAFENIB
1269440-17-6
8L7891MRB6
A13226
AC-30230
AS-35201
BCP08458
BDBM221688
Braftovi
Braftovi (TN)
Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester
CHEMBL3301612
CMJCXYNUCSMDBY-ZDUSSCGKSA-N
CS-2289
D11053
DB11718
DTXSID00155347
Encorafenib (JAN/USAN/INN)
Encorafenib (LGX818)
Encorafenib [USAN:INN]
EX-A1587
GTPL7908
HY-15605
LGX 818
LGX-818
LGX-818(Encorafenib)
LGX818
Methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate
methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
MFCD25976758
NCGC00378599-03
NVP-LGX818
NVP-LGX818-NXA
s7108
SB16926
SCHEMBL8228295
UNII-8L7891MRB6
US9314464, 9
ZINC68249103

US Patents and Regulatory Information for ENCORAFENIB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-001 Jun 27, 2018 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ENCORAFENIB

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2470526 LUC00101 Luxembourg   Start Trial PRODUCT NAME: BRAFTOVI - ENCORAFENIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1314 20180924
2470526 300973 Netherlands   Start Trial DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME
2470526 CA 2019 00012 Denmark   Start Trial PRODUCT NAME: ENCORAFENIB I ALLE FORMER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/18/1314 20180924
2470526 122019000021 Germany   Start Trial PRODUCT NAME: ENCORAFENIB IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/18/1314 20180920
2727918 PA2019006 Lithuania   Start Trial PRODUCT NAME: BINIMETINIBO IR ENKORAFENIBO, KIEKVIENO BET KURIOMIS FORMOMIS, KURIOMS TAIKOMA PAGRINDINIO PATENTO APSAUGA, DERINYS; REGISTRATION NO/DATE: EU/1/18/1314, EU/1/18/1835 20190920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Dow
McKesson
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.